Pharmacotherapy for Preeclampsia in Low and Middle Income Countries: An Analysis of Essential Medicines Lists

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 3, 2013, Pages 215-223

  Lalani, Shifana ^a   Firoz, Tabassum ^a   Magee, Laura A ^a,b   Sawchuck, Diane ^a,c   Payne, Beth ^a   Gordon, Rebecca ^a   Vidler, Marianne ^a   von Dadelszen, Peter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antihypertensive agent; Eclampsia; Essential medicine list; Preeclampsia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DEXAMETHASONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; GLUCONATE CALCIUM; HEPARIN; HYDRALAZINE; HYDRAZINE; LISINOPRIL; LOSARTAN; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; MISOPROSTOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; OXYTOCIN; PRAZOSIN; PROPRANOLOL; PROSTANOID; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL; BETAMETHASONE; DIURETIC AGENT; FIBRINOLYTIC AGENT; GLUCOCORTICOID; OXYTOCIC AGENT; UTERUS SPASMOLYTIC AGENT;

ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; ECLAMPSIA; FEMALE; HUMAN; HYPERTENSION; LABOR INDUCTION; LOW INCOME COUNTRY; LUNG EDEMA; MIDDLE INCOME COUNTRY; PREECLAMPSIA; PREMATURE LABOR; PREVALENCE; THROMBOSIS; WORLD HEALTH ORGANIZATION; PREGNANCY; THROMBOEMBOLISM;

ANTIHYPERTENSIVE AGENTS; BETAMETHASONE; DEVELOPING COUNTRIES; DEXAMETHASONE; DIURETICS; ECLAMPSIA; FEMALE; FIBRINOLYTIC AGENTS; GLUCOCORTICOIDS; HEPARIN; HUMANS; MAGNESIUM SULFATE; OXYTOCICS; OXYTOCIN; PRE-ECLAMPSIA; PREGNANCY; PULMONARY EDEMA; THROMBOEMBOLISM; TOCOLYTIC AGENTS;

EID: 84883823708     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30993-2     Document Type: Article

References (37)

1. Khan K.S., Wojdyla D., Say L., Gulmezoglu A.M., Van Look P.F. A. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009, 33:130-137.
3. vonDadelszen P., Magee L. What matters in preeclampsia are the associated adverse outcomes: the view from Canada. Curr Opin Obstet Gynecol 2008, 20:110-115.
4. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia 2011, World Health Organization, Geneva.
5. Firoz T., Sanghvi H., Merialdi M., von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol 2011, 25:537-548.
6. World Health Organization. The world drug situation 1988, World Health Organization, Geneva.
7. Laing R., Waning B., Gray A., Ford N., Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet 2003, 361:1723-1729.
8. WHO Expert Committee. The selection and use of essential medicines. World Health Organization Technical Report Series, unedited edition 2011, 1-125. Available at:, Accessed on December 19, 2012. http://www.who.int.
9. Kishore S.P., Herbstman B.J. Adding a medicine to the WHO model list of essential medicines. Clin Pharmacol Ther 2009, 85:237-239.
10. United Nations. The Millennium Development Goals report 2011, United Nations, New York.
11. World Bank. Country and lending groups 2012, The World Bank Group, Washington, DC:.
12. World Health Organization. Medicines publication and documentation [Internet] 2011, World Health Organization, Geneva, [updated 2012 May 27; cited 2012 June 11]. Available from:. http://apps.who.int/medicinedocs/en.
13. World Health Organization. World Health Organization collections [Internet] 2011, World Health Organization, Geneva, [updated 2012 May 27; cited 2012 June 11]. Available from:. http://www.who.int.
14. World Health Organization. Trends in maternal mortality: 1990-2010 2012, World Health Organization, Geneva.
15. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995, 345:1455-1463.
16. Altman D., Carroli G., Duley L., Farrell B., Moodley J., Neilson J., et al. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
17. Aaserud M., Lewin S., Innvaer S., Paulsen E.J., Dahlgren A.T., Trommald M., et al. Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia. BMC Health Serv Res 2005, 5:68.
18. Sevene E., Lewin S., Mariano A., Woelk G., Oxman A.D., Matinhure S., et al. System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe. BMJ 2005, 331:765-769.
19. Twagirumukiza M., Annemans L., Kips J.G., Bienvenu E., VanBortel L.M. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. Trop Med Int Health 2010, 15:350-361.
20. Magee L.A., Helewa M., Moutquin J.M., von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008, 30(3 Suppl):S1-S48.
21. ACOG Committee on Obstetric Practice. Emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia 2011, ACOG Committee Opinion, No. 514, December 2011.
22. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007, (1):CD002252.
23. Magee L.A., Cham C., Waterman E.J., Ohlsson A., von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: metaanalysis. BMJ 2003, 327:955-964.
24. Lewis G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers' lives: reviewing maternal deaths to make motherhood safer 2003-2005. The seventh report of the Confidential Enquiries into Maternal Deaths in the United Kingdom 2007, CEMACH, London.
25. Steegers E.A., vonDadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
26. World Health Organization. Priority medicines for mothers and children 2011, World Health Organization, Geneva.
27. Duley L., Henderson-Smart D.J., Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006, (3):CD001449.
28. Cotton D.B., Gonik B., Dorman K.F. Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulfate. Am J Obstet Gynecol 1984, 148:162-165.
29. Mroczek W.J., Lee W.R., Davidov M.E. Effect of magnesium sulfate on cardiovascular hemodynamics. Angiology 1977, 28:720-724.
30. Pritchard J.A. The use of the magnesium ion in the management of eclamptogenic toxemias. Surg Gynecol Obstet 1955, 100:131-140.
31. Young B.K., Weinstein H.M. Effects of magnesium sulfate on toxemic patients in labor. Obstet Gynecol 1977, 49:681-685.
32. World Health Organization. WHO recommendations for induction of labour 2011, World Health Organization, Geneva.
33. Alfirevic Z., Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2006, (1):CD001338. [updated 2010];.
34. Kelly A.J., Malik S., Smith L., Kavanagh J., Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2009, (4):CD003101.
35. Yang H., Dib H.H., Zhu M., Qi G., Zhang X. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan 2010, 25:219-229.
36. World Health Organization. Universal access to reproductive health: accelerated actions to enhance progress on Millennium Development Goal 5 through advancing Target 5B 2011, World Health Organization, Geneva.
37. Shaw D., Cook R.J. Applying human rights to improve access to reproductive health services. Int J Gynaecol Obstet 2012, 119(Suppl 1):S55-S59.